At what age should an average‑risk woman stop routine screening mammography?

When to Stop Routine Screening Mammography in Average-Risk Women

For average-risk women, discontinue routine screening mammography at age 75 or when life expectancy falls below 10 years, whichever comes first. 1

Age-Based Stopping Framework

Standard Stopping Age

• Age 75 represents the recommended threshold for discontinuing routine mammography screening in average-risk women, as the American College of Physicians explicitly recommends stopping at this age unless specific conditions warrant continuation 1
• The decision at age 75 should trigger a formal assessment of health status rather than automatic cessation, but routine screening should end at this point for most women 2

Life Expectancy Criterion

• Stop screening when life expectancy drops below 10 years, regardless of chronological age, because it takes approximately 11 years on average before 1 death from breast cancer is prevented per 1000 women screened 1
• Women aged 75 with serious comorbid conditions (such as chronic obstructive pulmonary disease, heart failure, end-stage liver disease, end-stage renal failure, or dementia) have an average life expectancy of only 9 years, making them poor candidates for continued screening 1

Evidence Supporting Age 75 Cutoff

Mortality Benefit Timeline

• The long lag time between mammography and breast cancer mortality reduction (averaging nearly 11 years) means women must survive long enough to realize any screening benefit 1
• Women aged 75 with no comorbid conditions have an average life expectancy of 15 years, while those with serious comorbidities average only 9 years 1

Guideline Consensus

• The USPSTF concludes there is insufficient evidence to assess benefits and harms of screening in women 75 years or older, neither recommending for nor against it 3
• Most major guidelines converge on discontinuing screening when life expectancy is unlikely to exceed 10 years based on advanced age or comorbid conditions 1

Exceptions: When to Continue Beyond Age 75

Health Status Considerations

• Continue screening beyond age 75 only if overall health is excellent and life expectancy clearly exceeds 10 years, as more than one-third of all breast cancer deaths occur in women diagnosed after age 70 2
• Women aged 75 with no comorbidities have sufficient life expectancy (15 years) to potentially benefit from continued screening 1

Competing Risks Assessment

• The decision must incorporate competing risks for other causes of death, particularly in women with chronic conditions that significantly limit longevity 1
• Use validated tools like the Charlson Comorbidity Index to estimate life expectancy and determine whether screening benefits outweigh harms 2

Harms That Increase With Continued Screening

False Positives and Overdiagnosis

• Continuing screening increases false-positive results and overdiagnosis risk, with approximately 10% of screening mammograms resulting in recall for additional imaging 4
• The risk of diagnosing and treating breast cancer that would never have threatened health during the woman's lifetime increases with age 4

Unnecessary Procedures

• Older women face increased anxiety and unnecessary biopsies from false-positive results, with harms outweighing mortality benefits when life expectancy is limited 1

Common Pitfalls to Avoid

Do Not Use Age 75 as Automatic Cutoff

• Avoid reflexively stopping screening at exactly age 75 without assessing individual health status, as some healthy women may benefit from continued screening 2
• However, do not continue screening indefinitely—age 75 should trigger a formal reassessment, with most women stopping at this point 1

Do Not Screen Women With Limited Life Expectancy

• Never continue screening in women with severe comorbidities (heart failure, dementia, end-stage organ disease) or life expectancy under 10 years, as harms definitively outweigh benefits 1, 2
• Screening tests in this scenario should be explicitly avoided, as the American College of Physicians recommends 2

Do Not Ignore Competing Mortality Risks

• Failing to account for competing causes of death leads to inappropriate screening continuation in women who will not live long enough to benefit 1
• A 70-year-old woman with serious comorbidities has only 11 years average life expectancy, making her a marginal candidate even before age 75 1

Practical Implementation Algorithm

At age 75:

1. Assess overall health status and comorbidity burden using validated tools 2
2. Estimate life expectancy based on age and comorbid conditions 1
3. If life expectancy < 10 years: Stop screening 1, 2
4. If life expectancy ≥ 10 years and excellent health: Consider continuing with shared decision-making, discussing 15-20% mortality reduction against false-positive and overdiagnosis risks 2
5. For most women: Discontinue routine screening at age 75 1